Goldman Sachs has initiated coverage on Revvity Inc (RVTY) with a Neutral rating as of December 8, 2025. This marks the firm's first assessment of the company, which operates in the Life Sciences Tools & Services industry and is headquartered in Waltham, Massachusetts.
Revvity provides health science solutions and technologies, employing 11,000 full-time staff. The company focuses on areas such as translational multi-omics technologies, biomarker identification, and informatics. As of December 4, 2025, Revvity has a market capitalization of $11.7 billion, a P/E ratio of 49.19, and an EPS of 1.99, with a dividend yield of 27.1%.
Upcoming earnings are scheduled for July 27, 2026, with an estimated EPS of $1.36 and revenue of $752.8 million. Analyst consensus currently stands at 6 Strong Buy, 10 Buy, 8 Hold, 1 Sell, and 0 Strong Sell, indicating a general Buy outlook among analysts.
Analyst ratings, such as this one from Goldman Sachs, reflect professional opinions based on research and financial models. They are one of many inputs investors should consider alongside company fundamentals and industry trends.